^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Liposarcoma
    Drug:Aliqopa (copanlisib) (PIK3CA inhibitor, PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

    Published date:
    05/13/2020
    Excerpt:
    35 pts were enrolled (from 8/2/18 to 12/27/18), of which, 28 pts were available for analysis...Partial responses were seen in uterine cancer, clear cell carcinoma of anterior abdominal wall, and liposarcoma….Copanlisib showed meaningful clinical activity across various tumors with PIK3CA mutation in the late-line refractory setting.
    DOI:
    10.1200/JCO.2020.38.15_suppl.3506
    Trial ID:
    NCI-MATCH